专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170326166A1 COMPOSITIONS AND METHODS FOR TREATING PITUITARY TUMORS 审中-公开
公开(公告)号：US20170326166A1
公开(公告)日：2017-11-16
申请号：US15519702
申请日：2015-10-19
申请人： University of Virginia Patent Foundation
发明人： Edward H. Oldfield
IPC分类号： A61K31/7004 , A61K38/25 , A61K38/09 , A61K9/00 , A61K38/06 , A61K31/155 , A61K38/28 , A61K38/22
CPC分类号： A61K31/7004 , A61K9/0019 , A61K31/12 , A61K31/155 , A61K31/353 , A61K31/357 , A61K38/066 , A61K38/09 , A61K38/2228 , A61K38/25 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The present application discloses that pituitary tumor cells are sensitive to low concentrations of glucose and that methods of treating such tumors include methods to induce infarction that are designed to inhibit glucose uptake, reduce intracellular glucose levels, inhibit glucose utilization, or to reduce available glucose to the tumor or the tumor cells.

2. 发明申请

US20170182129A1 SYSTEMIC DELIVERY OF VIRUS VECTORS ENCODING UROCORTIN-2 AND RELATED GENES TO TREAT DIABETES-RELATED CARDIAC DYSFUNCTIONS AND CONGESTIVE HEART FAILURE 审中-公开
公开(公告)号：US20170182129A1
公开(公告)日：2017-06-29
申请号：US15301703
申请日：2015-04-03
申请人： The Regents of the University of California
发明人： Kirk H. Hammond , Mei Hua Gao
IPC分类号： A61K38/22 , C07K14/575 , A61K48/00
CPC分类号： A61K38/2228 , A61K48/00 , A61K48/005 , C07K14/57509
摘要： In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (CHF) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (AAV), e.g., an AAV8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (T2DM), e.g., by IV administration, thereby treating, ameliorating or protecting against (preventing) the T2DM and/or the diabetes-related cardiac dysfunction in the individual or patient.

3. 发明授权

US09555032B2 Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling 有权
标题翻译：通过调节CRF受体信号传导治疗和预防tau蛋白病和淀粉样蛋白β淀粉样变性的方法
公开(公告)号：US09555032B2
公开(公告)日：2017-01-31
申请号：US12663805
申请日：2008-06-13
申请人： Robert A. Rissman , Kuo-Fen Lee , Wylie W. Vale , Paul E. Sawchenko
发明人： Robert A. Rissman , Kuo-Fen Lee , Wylie W. Vale , Paul E. Sawchenko
IPC分类号： A61K31/519 , A61K45/06 , A61K38/22 , G01N33/68
CPC分类号： A61K31/519 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0318 , A61K9/0019 , A61K38/2228 , A61K45/06 , G01N33/6896 , G01N2440/14 , G01N2500/00 , G01N2800/2814 , G01N2800/2821 , A61K2300/00
摘要： Methods for treating or preventing tauopathies and/or Aβ amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer's disease by administration of CRF-R1 selective antagonist are provided.
摘要翻译：通过调节CRF受体信号传导治疗或预防tau蛋白病和/或Aβ淀粉样变性的方法。通过施用CRF-R1选择性拮抗剂和/或CRF-R2选择性激动剂可以减少CNS中超磷酸化tau蛋白的积累。例如，在一些方面，提供了通过施用CRF-R1选择性拮抗剂来预防阿尔茨海默病发作的方法。

4. 发明申请

US20150315257A1 UROCORTIN 2 ANALOGS AND USES THEREOF 审中-公开
标题翻译： UROCORTIN 2模拟及其用途
公开(公告)号：US20150315257A1
公开(公告)日：2015-11-05
申请号：US14802812
申请日：2015-07-17
申请人： Research Development Foundation , Research Development Foundation
发明人： Wylie W. VALE, JR. , Joan M. VAUGHAN , Cindy DONALDSON , Wolfgang FISCHER , Jean E. F. RIVIER
IPC分类号： C07K14/47
CPC分类号： A61K38/2228 , C07K14/4705 , C07K14/57509 , Y10T428/13
摘要： Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention.
摘要翻译：公开的是具有类似于尿皮质素2但具有与尿皮质素2相比具有改善的水溶性的药理学活性的尿皮质素2的类似物的多肽和本发明的多肽的药物组合物。还公开了编码多肽的多核苷酸，以及使用本发明的多肽和多核苷酸的药物组合物治疗病理生理状态的方法。此外，所公开的是包含编码本发明多肽的核酸的载体和宿主细胞，以及包括本发明的药物组合物的试剂盒。

5. 发明申请

US20140072530A1 TREATMENT OF HIV 审中-公开
标题翻译：治疗艾滋病毒
公开(公告)号：US20140072530A1
公开(公告)日：2014-03-13
申请号：US14080693
申请日：2013-11-14
申请人： AIMSCO LIMITED
发明人： Deirdre McIntosh
IPC分类号： A61K38/22 , A61K38/18 , A61K38/17 , A61K38/34 , A61K38/35 , A61K38/33 , A61K38/16 , A61K38/20
CPC分类号： A61K38/2228 , A61K38/16 , A61K38/1709 , A61K38/1774 , A61K38/1841 , A61K38/2066 , A61K38/22 , A61K38/33 , A61K38/34 , A61K38/35 , A61K2300/00
摘要： We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation and medicaments.
摘要翻译：我们描述了使用促皮质素皮质素（POMC）和促肾上腺皮质激素释放因子（CRF）肽及其产物治疗HIV的方法，以及这些肽在制备和药物中的用途。

6. 发明申请

US20110105397A1 METHOD FOR TREATING HEART FAILURE WITH STRESSCOPIN-LIKE PEPTIDES 审中-公开
标题翻译：用类似抗抑郁肽处理心脏衰竭的方法
公开(公告)号：US20110105397A1
公开(公告)日：2011-05-05
申请号：US12940019
申请日：2010-11-04
申请人： Peter J. Gengo , Hani N. Sabbah , Nigel P. Shankley
发明人： Peter J. Gengo , Hani N. Sabbah , Nigel P. Shankley
IPC分类号： A61K38/22 , A61P9/04
CPC分类号： A61K38/2228
摘要： The present invention relates to novel methods of treating heart failure comprising administering an amount of stresscopin-like peptide to a subject in need thereof; and substantially maintaining the amount of said peptide present in the plasma of said subject at a concentration resulting in a therapeutic benefit without a substantial increase in the heart rate of said subject. The method involves the use of stresscopin-like peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists.
摘要翻译：本发明涉及治疗心力衰竭的新方法，包括向有需要的受试者施用一定量的应激素样肽; 并且以导致治疗益处的浓度基本上保持存在于所述受试者的血浆中的所述肽的量，而不显着增加所述受试者的心率。该方法包括使用选择性促肾上腺皮质激素释放激素受体2型（CRHR2）激动剂的应激素样肽。

7. 发明授权

US07815905B2 Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors 有权
标题翻译：通过施用促肾上腺皮质激素释放因子受体-2抑制剂来增加胰岛素敏感性或降低胰岛素分泌的方法
公开(公告)号：US07815905B2
公开(公告)日：2010-10-19
申请号：US11668047
申请日：2007-01-29
申请人： Alon M. Chen , Kuo-Fen Lee , Chien Li , Wylie W. Vale
发明人： Alon M. Chen , Kuo-Fen Lee , Chien Li , Wylie W. Vale
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： A61K38/2228
摘要： In some aspects, the invention relates to methods for increasing insulin-sensitivity and/or decreasing insulin secretion in an individual by reducing or inhibiting corticotropin releasing factor 2 (CRFR2) signaling. CRFR2 antagonists may block agonism by one or more CRFR2 agonist, for example Ucn 2 or Ucn 3. Methods according to the invention may be use to treat a variety of metabolic diseases such as type 2 diabetes, metabolic syndrome, nonalcoholic fatty liver disease, polycystic ovarian syndrome and obesity.
摘要翻译：在一些方面，本发明涉及通过减少或抑制促皮质激素释放因子2（CRFR2）信号传导来增加个体中胰岛素敏感性和/或降低胰岛素分泌的方法。 CRFR2拮抗剂可以阻断一种或多种CRFR2激动剂（例如Ucn 2或Ucn 3）的激动作用。根据本发明的方法可用于治疗各种代谢疾病如2型糖尿病，代谢综合征，非酒精性脂肪性肝病，多囊性卵巢综合征和肥胖。

8. 发明申请

US20100203048A1 METHODS OF USING CORTICOTROPIN-RELEASING FACTOR FOR THE USE OF THE TREATMENT OF CANCER 审中-公开
标题翻译：使用治疗癌症的方法使用柯里朋素释放因子
公开(公告)号：US20100203048A1
公开(公告)日：2010-08-12
申请号：US12686231
申请日：2010-01-12
申请人： Stephen Evans-Freke
发明人： Stephen Evans-Freke
IPC分类号： A61K39/395 , A61P35/00 , A61P35/04
CPC分类号： A61K38/2228 , A61K38/00 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , A61K2300/00
摘要： Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF).
摘要翻译：本文提供了一种通过施用高剂量的促肾上腺皮质激素释放因子（CRF）来治疗人类的癌症的方法。

9. 发明申请

US20060003937A1 Urocortin-III and uses thereof 有权
公开(公告)号：US20060003937A1
公开(公告)日：2006-01-05
申请号：US11214371
申请日：2005-08-29
申请人： Wylie Vale , Kathy Lewis , Marilyn Perrin , Koichi Kunitake , Jean Rivier , Jozsef Gulyas
发明人： Wylie Vale , Kathy Lewis , Marilyn Perrin , Koichi Kunitake , Jean Rivier , Jozsef Gulyas
IPC分类号： A61K38/22 , C07K14/59
CPC分类号： A61K38/2228 , A61K38/00 , C07K14/57509 , C07K14/695
摘要： A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.

10. 发明授权

US5780431A Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form 失效
标题翻译：具有改善液体稳定性的促肾上腺皮质激素释放因子的药物制剂
公开(公告)号：US5780431A
公开(公告)日：1998-07-14
申请号：US717306
申请日：1996-09-20
申请人： Bert Ho , Behzad Khosrovi , Pamela G. Hirtzer
发明人： Bert Ho , Behzad Khosrovi , Pamela G. Hirtzer
IPC分类号： A61K38/04 , A61K38/22 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/26 , A61P29/00 , A61K38/35 , A61K38/00 , C07K14/575
CPC分类号： A61K47/12 , A61K38/2228 , A61K47/10 , A61K47/18 , A61K47/26 , A61K9/0019
摘要： The present invention relates to novel formulations of corticotropin releasing factor (CRF) having improved stability during storage over extended periods of time as liquids, which retain significant pharmaceutical activity during such storage and/or which are physiologically compatible. The formulations of the present invention comprise (a) a pharmaceutically effective concentration of CRF, (b) a buffer to maintain the pH of the formulation between about 2.0 to about 5.0 or about 6.0 to about 9.0 when in liquid form and (c) an alcohol such as mannitol, sorbitol, methanol, glycerol, or the like. Other aspects of the present invention involve addition of various other components to the formulations described herein for the purpose of decreasing the rate of degradation of the CRF peptide or increasing its solubility in solution. Finally, the present invention is further directed to methods for preparing such novel pharmaceutical formulations of CRF and methods of using those formulations to reduce inflammation and edema in mammals.
摘要翻译：本发明涉及促血管激素释放因子（CRF）的新制剂，其在作为液体的长时间储存期间具有改善的稳定性，其在这种储存期间保持显着的药物活性和/或与其生理相容。本发明的制剂包含（a）药物有效浓度的CRF，（b）当液体形式时，将制剂的pH维持在约2.0至约5.0或约6.0至约9.0之间的缓冲剂，和（c）醇如甘露醇，山梨糖醇，甲醇，甘油等。本发明的其它方面涉及为了降低CRF肽的降解速率或增加其在溶液中的溶解度的目的，向本文所述的制剂中加入各种其它组分。最后，本发明进一步涉及制备这种新型CRF药物制剂的方法以及使用这些制剂减少哺乳动物炎症和水肿的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式